Physician profile
Grace K Tee
NPI 1689691461
$17,479.98
in general payments reported to CMS, 2019-2025
53 companies · $2,488 in 2025
The $2,488 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,052 · 2020: $1,944 · 2021: $2,715 · 2022: $2,666 · 2023: $2,299 · 2024: $2,316 · 2025: $2,488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,042 · Education: $61.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,041.69 |
| Education | $61.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,631.25 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $1,506.86 | 2019-2023 | Xarelto |
| Pfizer INC. | $1,429.22 | 2019-2025 | |
| Abbvie INC. | $1,381.19 | 2020-2025 | Vraylar, Linzess, Viberzi |
| Lilly USA, LLC | $1,282.15 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $1,243.57 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,144.98 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,118.51 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $716.13 | 2019-2025 | Eliquis, Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $679.96 | 2021-2025 | |
| Amarin Pharma, INC. | $623.64 | 2019-2022 | |
| Abbott Laboratories | $504.51 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2, Cardiomems |
| Amgen INC. | $443.40 | 2020-2025 | Repatha, Otezla, Krystexxa |
| Novartis Pharmaceuticals Corporation | $405.12 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $253.09 | 2019-2022 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Tee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.